中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 39 Issue 5
May  2023
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(5): 1061-1069

Efficacy and safety of tenofovir alafenamide fumarate in treatment of chronic hepatitis B patients aged ≥60 years in Qingdao, China

DOI: 10.3969/j.issn.1001-5256.2023.05.010
  • 1.

    Department of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, Shandong 266000, China

  • 2.

    Department of Infectious Diseases, Qingdao Sixth People's Hospital, Qingdao, Shandong 266000, China

  • 3.

    Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China

  • 4.

    Department of Infectious Diseases, Chengyang People's Hospital, Qingdao, Shandong 266000, China

  • 5.

    Department of Infectious Diseases, Jimo People's Hospital, Qingdao, Shandong 266000, China

Research funding:

Chronic Hepatitis B Clinical Research Project (IN-CN-320-5837)

More Information
  • Corresponding author: XIN Yongning, xinyongning@163.com (ORCID: 0000-0002-3692-7655)
  • Received Date: 2022-10-25
  • Accepted Date: 2022-12-02
  • Published Date: 2023-05-20
    Abstract
  •   Objective  To investigate the application value of tenofovir alafenamide fumarate (TAF) in elderly patients with chronic hepatitis B (CHB) and its influence on bones and kidneys.  Methods  A total of 36 CHB patients, aged ≥60 years, who received TAF antiviral therapy in Qingdao Municipal Hospital, The Affiliated Hospital of Qingdao University, Qingdao Sixth People's Hospital, Chengyang People's Hospital, and Jimo People's Hospital from June 2021 to October 2022 were enrolled in this study, and all patients received TAF (25 mg/d) antiviral therapy. Related data were collected at baseline and weeks 24 and 48 of treatment, including virological indicators, biochemical parameters, urinary protein electrophoresis indices, transient elastography (FibroScan), and bone mineral density. Virological indicators included high-sensitivity HBV DNA quantification; biochemical parameters included total bilirubin, direct bilirubin (DBil), indirect bilirubin (IBil), alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, total bile acid (TBA), glucose, blood urea nitrogen, creatinine, estimated glomerular filtration rate, and cystatin C (Cys C); urinary protein electrophoresis indices included urinary β2 microglobulin (β2-MG), urinary retinol (URBP), and urinary α1 microspherin (α1-MG). The paired t-test was used for comparison of normally distributed continuous data before and after treatment, and the Wilcoxon signed-rank test was used for comparison of non-normally distributed continuous data before and after treatment; the chi-square test or the Fisher's exact test was used for comparison of categorical data.  Results  A total of 36 CHB patients completed 24 weeks of follow-up. The complete virological response rate after 24 weeks of treatment was higher than that at baseline [83.3% (30/36) vs 77.8% (28/36), χ2=0.36, P=0.55], and there were significant reductions in DBil (t=-2.42, P=0.02) and Cys C (t=-4.34, P < 0.001) from baseline to week 24. A total of 18 CHB patients completed 48 weeks of follow-up. The complete virological response rate after 48 weeks of treatment was higher than that at baseline (94.4% vs 77.8%, χ2=2.22, P=0.34), and there were significant increases in IBil (t=2.43, P=0.03), TBA (Z=-2.24, P=0.03), and bone mineral density T score of lumbar vertebra (t=2.92, P= 0.01) and femoral neck (t=2.42, P=0.03) and a significant reduction in liver stiffness measurement (t=-2.31, P=0.03). There were no significant changes in β2-MG, URBP, and α1-MG after treatment (all P > 0.05).  Conclusion  TAF has a good antiviral effect in CHB patients aged ≥60 years and can help more CHB patients achieve complete virological response, without causing damage to the kidney, and it can also improve bone mineral density and liver fibrosis degree.

     

    • FullText(HTML)
    • References(17)
  • [1]
    WANG H, MEN P, XIAO Y, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis[J]. BMC Infect Dis, 2019, 19(1): 811. DOI: 10.1186/s12879-019-4428-y.
    [2]
    LIU J, ZHANG S, WANG Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study[J]. Lancet Infect Dis, 2016, 16(1): 80-86. DOI: 10.1016/S1473-3099(15)00218-2.
    [3]
    LIU Z, LI M, HUTTON DW, et al. Impact of the national hepatitis B immunization program in China: a modeling study[J]. Infect Dis Poverty, 2022, 11(1): 106. DOI: 10.1186/s40249-022-01032-5.
    [4]
    ZHU JY, GAO M, SONG QY, et al. Prevalence of osteoporosis in Chinese elderly people: a Meta-analysis[J]. Chin Gen Pract, 2022, 25(3): 346-353. DOI: 10.12114/j.issn.1007-9572.2021.02.083

    朱洁云, 高敏, 宋秋韵, 等. 中国老年人骨质疏松症患病率的Meta分析[J]. 中国全科医学, 2022, 25(3): 346-353. DOI: 10.12114/j.issn.1007-9572.2021.02.083
    [5]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [6]
    AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681. DOI: 10.1016/j.jhep.2017.11.039.
    [7]
    Compilation committee of Chinese expert consensus on medical nutritional therapy for overweight/obesity. Chinese expert consensus on medical nutritional therapy for overweight/obesity (2016)[J]. Chin J Diabetes Mellitus, 2016, 8(9): 525-540. DOI: 10.3760/cma.j.issn.1674-5809.2016.09.004.

    中国超重肥胖医学营养治疗专家共识编写委员会. 中国超重/肥胖医学营养治疗专家共识(2016年版)[J]. 中华糖尿病杂志, 2016, 8(9): 525-540. DOI: 10.3760/cma.j.issn.1674-5809.2016.09.004.
    [8]
    NGUYEN MH, ATSUKAWA M, ISHIKAWA T, et al. Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir[J]. Am J Gastroenterol, 2021, 116(6): 1264-1273. DOI: 10.14309/ajg.0000000000001157.
    [9]
    FONG TL, LEE BT, TIEN A, et al. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide[J]. J Viral Hepat, 2019, 26(5): 561-567. DOI: 10.1111/jvh.13053.
    [10]
    LEE BT, CHANG M, LIM C, et al. Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients[J]. JGH Open, 2021, 5(2): 258-263. DOI: 10.1002/jgh3.12481.
    [11]
    BUTI M, GANE E, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206. DOI: 10.1016/S2468-1253(16)30107-8.
    [12]
    CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195. DOI: 10.1016/S2468-1253(16)30024-3.
    [13]
    PAPATHEODORIDIS GV, MIMIDIS K, MANOLAKOPOULOS S, et al. HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks[J]. Aliment Pharmacol Ther, 2022, 56(4): 702-712. DOI: 10.1111/apt.17093.
    [14]
    SURIAL B, BEGUELIN C, CHAVE JP, et al. Brief report: switching from TDF to TAF in HIV/HBV-coinfected individuals with renal dysfunction-a prospective cohort study[J]. J Acquir Immune Defic Syndr, 2020, 85(2): 227-232. DOI: 10.1097/QAI.0000000000002429
    [15]
    LUO X, QU Y, CAI XB, et al. Effects of antiviral therapy on the reversal of liver fibrosis[J]. J Clin Hepatol, 2022, 38(11): 2596-2598. DOI: 10.3969/j.issn.1001-5256.2022.11.032.

    罗昕, 曲颖, 蔡晓波, 等. 抗病毒治疗对肝纤维化逆转的影响[J]. 临床肝胆病杂志, 2022, 38(11): 2596-2598. DOI: 10.3969/j.issn.1001-5256.2022.11.032.
    [16]
    CHEN P, WEI W, JIN L, et al. Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B[J]. Exp Ther Med, 2021, 22(5): 1325. DOI: 10.3892/etm.2021.10760.
    [17]
    LI C, MA Y, YANG C, et al. Association of cystatin C kidney function measures with long-term deficit-accumulation frailty trajectories and physical function decline[J]. JAMA Netw Open, 2022, 5(9): e2234208. DOI: 10.1001/jamanetworkopen.2022.34208.
    • Relative Articles
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. 王静，王佳琪，陈芳，夏杰，李露锋，毛青. ALT正常的慢性乙型肝炎患者抗病毒治疗疗效和安全性的真实世界研究. 重庆医学. 2025(01): 138-141 .
    2. 何雄志. 红外肝病治疗仪联合富马酸丙酚替诺福韦治疗慢性乙型肝炎的临床效果. 中外医学研究. 2025(06): 36-39 .
    3. 唐海涛，王娴，周佳琦，王凤梅，张文华. 富马酸丙酚替诺福韦治疗初治失代偿期乙型肝炎肝硬化患者的临床研究. 肝脏. 2024(07): 830-833 .
    4. 付文鹏，慕少英. 富马酸丙酚替诺福韦治疗慢性乙型病毒性肝炎的临床疗效分析. 系统医学. 2024(23): 39-42 .

    Other cited types(2)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (957) PDF downloads(129) Cited by(6)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1659]YesterdayPV[2864]TodayIP[152]TodayPV[244]Online[10]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return